Healthcare platform company Klop Co., Ltd. announced on the 18th that it signed a business agreement (MOU) with the Korea Type 1 Diabetes Association to prevent blindness and promote fundus examinations for type 1 diabetes patients.
This agreement was created with the aim of expanding the blindness prevention campaign targeting type 1 diabetes patients with low regular eye examination rates and providing more practical medical accessibility through Klopp's eye health management platform 'AfterNoon'.
Type 1 diabetes is a chronic disease in which insulin is hardly secreted due to an autoimmune reaction. It often occurs in childhood and adolescence, and requires lifelong insulin treatment. Despite the large number of young patients, the rate of regular ophthalmological examinations to prevent long-term complications is still low.
The 'Afternoon' platform operated by Klopp supports fundus examinations of diabetic patients through linkages between internal medicine and ophthalmology medical institutions, and provides a referral-based medical delivery system that induces early diagnosis and treatment. As of now, approximately 3,000 patients have been referred through the platform, and of these, approximately 200 have been diagnosed with diabetic retinopathy early and are currently undergoing treatment.
Through this agreement, the two organizations plan to cooperate in the following areas: ▲jointly promoting an eye health campaign for type 1 diabetes patients, ▲providing guidance and support for the use of Afternoon-linked hospitals and clinics, and ▲developing and providing educational content to prevent blindness.
Kim Mi-young, the representative of the Korean Type 1 Diabetes Association, said, “Although many patients have been managing their blood sugar well, they have had difficulty getting eye exams due to environmental constraints.” She added, “The afternoon service has helped alleviate this inconvenience, and we hope that this collaboration will help more patients manage their eye health.”
Klop CEO Park Sang-jun said, “Since type 1 diabetes tends to develop early, early response to ophthalmic complications is especially important,” adding, “With this agreement as an opportunity, we will continue to advance our technology and services so that we can make a real contribution to preventing blindness.”
- See more related articles
You must be logged in to post a comment.